Is é radaiteiripe beacht an modh cóireála ailse is tábhachtaí. Is féidir le teicnící beachta radaiteiripe arna léiriú ag scian tosaigh tapa, scian prótón, ian trom, etc., máinliacht radacach agus cóireáil chúnta a dhéanamh d'othair ailse. To understand the progress of radiotherapy, sarcoma is more common in young people, is a malignant tumor derived from mesenchymal tissue (including connective tissue and muscle). Sarcomas are highly malignant and develop rapidly! Common sarcomas include osteosarcoma, leiomyoma, lymphosarcoma, synovial sarcoma, etc.
Is é an modh is fearr le sarcoma ná máinliacht. D'fhonn leigheas radacach a lorg, is gnách go n-éilíonn dochtúirí tí othair ar a gcuid géaga a theascadh. , Tá an chuid is mó othar deacair a chóireáil. Níl sarcoma íogair do cheimiteiripe. Tá sé deacair freisin gnáth-radaiteiripe siadaí a mharú, agus tá seans maith go mbeidh metastasis tríd an fhuil ag leiomyoma, lymphosarcoma, agus sarcoma synovial. Dá bhrí sin, caithfear cóireáil sarcoma a luaithe agus is féidir agus a luaithe is féidir.
The EDGE Radiosurgery system (EDGE radiosurgery meall treatment system) was developed by the American Varian company and was approved by the US FDA on January 23, 2013. The EDGE blade is by far the most effective non-invasive tumor removal technology, using the unique FDA’s Calypso® GPS for the Body® system and surface beam monitoring system approved on July 21, 2014 with high-frequency real-time dynamics of up to 10 ms Monitor and lock the tumor “escape” during the treatment process, combined with the new generation IGRT and other image guidance technology, using the unique high-intensity HD-MLC collimator up to 2400MU / min to remove tumor tissue with sub-millimeter accuracy with almost no residue .
Is féidir le saintréithe uathúla scian luas EDGE, radaíocht ard-déine suas le 2400MU / min, an DNA de chealla meall a bhriseadh go tapa, agus ar deireadh thiar ina chúis le bás na cealla meall, agus an meall a ionsú nó a scarred. Tá cruinneas an scian EDGE chomh hard le 0.1mm.
